Feasibility of the Mobile Mindfulness-Based Stress Reduction for Breast Cancer (mMBSR(BC)) Program for Symptom Improvement among Breast Cancer Survivors.

Feasibility of the Mobile Mindfulness-Based Stress Reduction for Breast Cancer (mMBSR(BC)) Program for Symptom Improvement among Breast Cancer Survivors.

Psychooncology. 2017 Jun 30;:

Authors: Lengacher CA, Reich RR, Ramesar S, Alinat CB, Moscoso M, Cousin L, Marino VR, Elias MN, Paterson CL, Rodriguez CS, Wang HL, Kip KE, Meng H, Park JY

Abstract
OBJECTIVE: The purpose of this pilot study was to test the feasibility of delivering the mobile Mindfulness-Based Stress Reduction for Breast Cancer (mMBSR(BC)) program using an iPad and to evaluate its impact on symptom improvement.
METHODS: A single group, pre-posttest design was implemented among female stages 0-III breast cancer survivors (BCS) who completed treatment. Data were collected at baseline and week 6 on measures of psychological and physical symptoms and quality of life. The mMBSR(BC) program is a standardized, stress-reducing intervention that combines sitting and walking meditation, body scan and yoga and is designed to deliver weekly 2-hour sessions for 6 weeks using an iPad.
RESULTS: The mean age of the 15 enrolled BCS was 57 years; one participant was non-Hispanic Black, and 14 were non-Hispanic White. Of the 13 who completed the study, there were significant improvements from baseline to 6 weeks post-mMBSR(BC) in psychological and physical symptoms of depression, state anxiety, stress, fear of recurrence, sleep quality, fatigue and quality of life (p's < 0.05). Effect sizes for improvements of multiple symptoms ranged from medium to large.
CONCLUSIONS: These results provide preliminary support that the mMBSR(BC) program may be feasible and acceptable, showing a clinical impact on decreasing psychological and physical symptoms. This mobile-based program offers a delivery of a standardized MBSR(BC) intervention to BCS that is convenient for their own schedule while decreasing symptom burden in the survivorship phase after treatment for breast cancer.

PMID: 28665541 [PubMed - as supplied by publisher]

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2ss24YU
via IFTTT